Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (scientific article published on 01 April 2019)

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Q33408750

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Q33435836

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Q34049228

Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer

Q36127897

Limitations to the use of carboplatin-based therapy in advanced ovarian cancer

Q36382337

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

Q36822179

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Q38393818

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Q38549680

FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer

Q38656596

Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance

Q40247915

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study

Q44794514

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer

Q45072382

Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer

Q45109769

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Q46029695

Cancer statistics, 2018.

Q47191906

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Q47237809

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Q50539670

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.

Q53791009

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

Q55285332

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Q56967070

Safety and dose modification for patients receiving niraparib

Q56968861

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

Q60955766

P433

issue

P921

main subject

ovarian cancer

Q172341

multicenter clinical trial

Q6934595

phase II clinical trial

Q42824440

P304

page(s)

636-648

P577

publication date

2019-04-01

P1433

published in

Lancet Oncology Commission

Q13747613

P1476

title

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

P478

volume

Reverse relations

cites work (P2860)

Q104734654	A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Q90399238	ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Q94587270	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
Q98158111	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study
Q90827979	Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations
Q100433540	Clinical assays for assessment of homologous recombination DNA repair deficiency
Q90335052	Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma
Q99583268	Development of new medical treatment for epithelial ovarian cancer recurrence
Q92857995	Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?
Q97531496	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England
Q99710228	Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer
Q93043588	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Q89777478	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Q89659933	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Q92164257	PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca"
Q89581160	PARP and PARG inhibitors in cancer treatment
Q98386293	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
Q99238336	Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Q90677069	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
Q98945207	Poly(ADP-ribose) polymerase inhibition: past, present and future
Q90637825	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
Q96127375	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review
Q98164379	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Q100549033	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer
Q92847059	Treatment of recurrent epithelial ovarian cancer
Q90403688	Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series

P356	DOI	10.1016/S1470-2045(19)30029-4
P698	PubMed publication ID	30948273